Search results
Found 9093 matches for
On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then a little over an hour later the New England Journal of Medicine, retracted studies that were based on inaccessible data, provided by the Surgisphere corporation. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. Here is MORU’s statement in response to these events.
Emerging infections
Asia has long been the source of infectious diseases that have escalated into epidemics or pandemics, notably SARS-CoV-2 and influenza. As new pandemic threats continue to arise, research at MORU focuses on genomic and immunological surveillance of emerging infections, the development and evaluation of new methods of assessing therapeutics, and their large-scale assessment in order to inform policies and practices.